OncoCyte Corp (NYSE:OCX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “

OCX has been the subject of a number of other research reports. Benchmark Co. increased their price target on shares of OncoCyte Corp from $7.50 to $8.00 and gave the company a “speculative buy” rating in a report on Tuesday, June 7th. Canaccord Genuity reaffirmed a “buy” rating on shares of OncoCyte Corp in a report on Wednesday, June 15th.

Shares of OncoCyte Corp (NYSE:OCX) opened at 4.5701 on Thursday. The company’s market capitalization is $116.22 million. The stock has a 50 day moving average price of $4.02 and a 200-day moving average price of $4.44. OncoCyte Corp has a 12 month low of $2.45 and a 12 month high of $10.24.

OncoCyte Corp (NYSE:OCX) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. Analysts forecast that OncoCyte Corp will post $0.04 EPS for the current year.

OncoCyte Corp Company Profile

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

5 Day Chart for NYSE:OCX

Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.